KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Eli Lilly (LLY) over the last 17 years, with Q3 2025 value amounting to $8.8 billion.

  • Eli Lilly's Cash from Operations rose 13804.25% to $8.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $16.1 billion, marking a year-over-year increase of 16627.43%. This contributed to the annual value of $8.8 billion for FY2024, which is 10796.44% up from last year.
  • As of Q3 2025, Eli Lilly's Cash from Operations stood at $8.8 billion, which was up 13804.25% from $3.1 billion recorded in Q2 2025.
  • Eli Lilly's 5-year Cash from Operations high stood at $8.8 billion for Q3 2025, and its period low was -$311.9 million during Q4 2023.
  • Moreover, its 5-year median value for Cash from Operations was $1.7 billion (2023), whereas its average is $2.2 billion.
  • As far as peak fluctuations go, Eli Lilly's Cash from Operations plummeted by 11875.86% in 2023, and later surged by 89313.88% in 2024.
  • Quarter analysis of 5 years shows Eli Lilly's Cash from Operations stood at $2.3 billion in 2021, then dropped by 26.48% to $1.7 billion in 2022, then tumbled by 118.76% to -$311.9 million in 2023, then surged by 893.14% to $2.5 billion in 2024, then skyrocketed by 257.18% to $8.8 billion in 2025.
  • Its Cash from Operations stands at $8.8 billion for Q3 2025, versus $3.1 billion for Q2 2025 and $1.7 billion for Q1 2025.